Sonia G. De Villambrosia
Santander, CB, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.
Journal: American journal of hematology
Published: December 04, 2023
Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.
Journal: Clinical and translational science
Published: September 09, 2022
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
Journal: British journal of haematology
Published: July 20, 2022
Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
Journal: British journal of haematology
Published: July 11, 2022
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
Journal: Haematologica
Published: July 21, 2021
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.
Journal: Annals of hematology
Published: September 08, 2019
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Journal: Bone marrow transplantation
Published: February 27, 2019
DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers.
Journal: Haematologica
Published: October 27, 2018
Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation.
Journal: Haematologica
Published: January 02, 2015
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Journal: British journal of haematology
Published: August 28, 2014
Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis.
Journal: Haematologica
Published: April 26, 2014
Last Updated: 09/26/2026